AstraZeneca Caps Inhaler Costs at $35 to Aid Vulnerable Patients

AstraZeneca has reduced monthly inhaler costs to $35, aiming to help vulnerable asthma and chronic obstructive pulmonary disease patients without health insurance following a Senate Committee investigation.